Test whether atomoxetine retains WM / attention phenotype under Slc6a2 LOF or NET-matched blockade that abolishes NET-class attribution
Atomoxetine WM / attention phenotypes are often framed as NET orthosteric blockade, yet Xu is a Slc6a2/NET KO tool, Bymaster is NET-mechanism PFC NE/DA attribution, Gamo is a PFC WM phenotype with α2/D1 downstream challenge (α2 ≠ NET), and Michelson is an ADHD RCT phenotype — none score residual-positive under NET abolish. This discussion asks whether any residual atomoxetine WM / attention phenotype survives a Slc6a2 LOF or NET-matched blockade that abolishes NET-class attribution on the same panel.
Claim
On a pre-registered acute/subacute rodent (or NHP Gamo-class) WM / attention panel with an atomoxetine-alone arm, a NET genetic LOF (Slc6a2) or NET-matched blockade that abolishes NET-class attribution, and an atomoxetine-under-abolish arm: under the same condition that abolishes NET-class attribution, atomoxetine retains residual WM / attention phenotype ≥50% of atomoxetine-alone (WM / attention units as pre-specified; α/N pre-specified) — assumption-kill / net-insufficiency.
Why it matters
Atomoxetine WM / attention phenotypes are often framed as NET orthosteric blockade; Xu is a Slc6a2/NET KO tool prior, Bymaster is NET-mechanism PFC NE/DA attribution, Gamo is a PFC WM phenotype prior with α2/D1 downstream challenge (α2 ≠ NET), and Michelson is an ADHD RCT phenotype prior — none score residual-positive under NET abolish. N25 asks whether residual atomoxetine WM / attention phenotype survives a Slc6a2 LOF or NET-matched blockade that kills NET-class attribution — net-insufficiency assumption-kill. Especially distinct from N15 (modafinil residual under DAT-matched block — DAT ≠ NET); N22 (tyrosine residual under AMPT — AMPT ≠ NET LOF); N23 (guanfacine residual under α2A LOF / α2-antagonist — α2 ≠ NET; Gamo idazoxan×ATM is α2-downstream adjacent, not N25 claim); also N16–N21 / N24 ≠ N25; N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-atomoxetine under NET abolish that abolishes NET-class attribution H2H UNKNOWN; genetic WM necessity-abolish H2H UNKNOWN; PRIOR_ART PARTIAL (NET-mechanism attribution FOUND; residual-positive under abolish absent; phenotype/tool priors FOUND); soft-complete empty ≠ novelty / ≠ failure; N1–N24 ≠ proof.
Mechanism sketch
Net-insufficiency assumption-kill: atomoxetine moves WM / attention phenotypes and is framed as selective NET blockade (Bymaster: NET-selective PFC NE/DA elevation), with Slc6a2/NET KO as a genetic tool (Xu) and published WM/ADHD phenotype priors (Gamo PFC WM; Michelson ADHD RCT); no published head-to-head scores residual-positive atomoxetine WM / attention under a Slc6a2 LOF or NET-matched blockade that abolishes NET-class attribution on the same panel as a retained residual. Prefer a same-panel acute/subacute rodent (or NHP Gamo-class) WM / attention lock with atomoxetine ± Slc6a2 LOF or named NET-matched abolish condition before treating NET orthosteric blockade as sole-necessary for the atomoxetine phenotype; optional cell / SPR / NET occupancy overlay only if a named published abolish-verification system locks residual first (or as cheap parallel). NET-mechanism attribution (Bymaster 12431845) constrains the monoamine bridge but is not residual-under-abolish WM H2H; KO-tool prior (Xu 10769386) and phenotype priors (Gamo 20855046; Michelson 12411225) lack residual-under-NET-abolish arms; Gamo idazoxan/SCH23390 is α2/D1 downstream (α2 ≠ NET) — PRIOR_ART PARTIAL; do not invent residual-positive H2H; do not invent genetic WM necessity-abolish H2H; do not treat α2-downstream as NET abolish. Competing caveats: abolish condition fails to kill NET-class attribution / atomoxetine-alone null / underpowered strata / assay-identity mismatch (phenotype ≠ residual; NET-mechanism ≠ residual-under-abolish; α2-downstream Gamo idazoxan ≠ NET abolish; DAT-KO Ptukha ≠ NET LOF) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this (DAT ≠ NET); N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this; N20 ≠ this; N21 ≠ this; N22 ≠ this (AMPT ≠ NET LOF); N23 ≠ this (α2 ≠ NET); N24 ≠ this. NOT MB/MAOI (SERIES_FROZEN).
Prior art
- PMID 10769386 / DOI 10.1038/74839 — Xu: mice lacking the norepinephrine transporter (Slc6a2/NET KO) — prolonged NE clearance, elevated extracellular NE, antidepressant-like behaviour, psychostimulant locomotor supersensitivity (Nat Neurosci 2000) — KO tool prior; no atomoxetine WM/attention residual-under-abolish arm. doi.org HEAD 302 (PubMed DOI verified).
- PMID 12431845 / DOI 10.1016/S0893-133X(02)00346-9 — Bymaster: atomoxetine selective NET inhibitor; increases extracellular NE and DA in PFC (Neuropsychopharmacology 2002) — NET-mechanism attribution prior; no genetic/antagonist residual-under-abolish WM H2H. doi.org HEAD 302 (PubMed DOI verified).
- PMID 20855046 / DOI 10.1016/j.jaac.2010.06.015 — Gamo: atomoxetine (and MPH) enhance prefrontal WM in monkeys; benefit challenged by idazoxan (α2) or SCH23390 (D1) (JAACAP 2010) — WM phenotype prior + α2/D1 downstream mediation; α2 ≠ NET (not NET abolish residual/necessity). doi.org HEAD 302 (PMC2999884).
- PMID 12411225 / DOI 10.1176/appi.ajp.159.11.1896 — Michelson: once-daily atomoxetine ADHD RCT in children/adolescents (Am J Psychiatry 2002) — human attention phenotype prior; no NET-abolish residual arm. doi.org HEAD 302 (PubMed DOI verified).
Baseline claimed
Under NET genetic LOF (Slc6a2) or NET-matched blockade that abolishes NET-class attribution, atomoxetine still retains WM / attention phenotype on the same panel — or Bymaster 12431845 already proves residual under NET abolish — or Xu NET KO / Gamo / Michelson phenotype already constitutes residual-under-abolish or genetic WM necessity-abolish H2H — or Gamo idazoxan×ATM already is NET abolish — or N15 modafinil-DAT / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N20 Bacopa-AChE / N21 nicotine-nAChR / N22 tyrosine-AMPT / N23 guanfacine-alpha2 / N24 caffeine-A2A / N1–N24 already settle residual atomoxetine under NET abolish.
Baseline measured
Xu Slc6a2/NET KO tool LITERATURE without atomoxetine WM residual arm (PMID 10769386). Bymaster atomoxetine NET-selective PFC NE/DA LITERATURE NET-mechanism attribution not residual-under-abolish WM H2H (PMID 12431845). Gamo atomoxetine PFC WM + α2/D1 challenge LITERATURE phenotype prior; α2 ≠ NET (PMID 20855046). Michelson once-daily atomoxetine ADHD RCT LITERATURE phenotype prior without residual-under-abolish arm (PMID 12411225). Matched residual-positive atomoxetine under Slc6a2 LOF or NET-matched block that abolishes NET-class attribution UNKNOWN (soft-complete Q_resid_tight NON-MATCH residual-positive; Q_xu_atom=0; Q_atom_net_ko=DAT-KO NON-MATCH 36291693; genetic WM necessity-abolish H2H NOT FOUND). Residual atomoxetine phenotype ≥50% of atomoxetine-alone when NET-class attribution abolished PREDICTION. N15 ≠ N25 (DAT ≠ NET); N16 ≠ N25; N17 ≠ N25; N18 ≠ N25; N19 ≠ N25; N20 ≠ N25; N21 ≠ N25; N22 ≠ N25 (AMPT ≠ NET LOF); N23 ≠ N25 (α2 ≠ NET); N24 ≠ N25; N1–N24 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof; do not invent residual; do not invent necessity kill.
Actionable limitations
- Do not treat N1–N24 as proving N25 — especially N15 ≠ N25 (DAT ≠ NET; Ptukha 36291693 is DAT-KO×atomoxetine NON-MATCH); N22 ≠ N25 (AMPT catecholamine-depletion ≠ NET LOF); N23 ≠ N25 (α2 ≠ NET; Gamo idazoxan×ATM is α2-downstream adjacent, not NET abolish); N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched; N20 is Bacopa residual under donepezil/AChE occupancy match; N21 is nicotine residual under mecamylamine/nAChR block; N24 is caffeine residual under Adora2a/A2A abolish; soft-complete empty ≠ demonstrated residual gain.
- NET-mechanism attribution FOUND — Bymaster 12431845 constrains monoamine bridge — PRIOR_ART PARTIAL OK, not auto-REJECT; do not invent residual-positive H2H from mechanism literature; do not invent genetic WM necessity-abolish H2H (soft-complete empty). Phenotype/tool ≠ residual — Xu 10769386 KO tool; Gamo 20855046 WM + α2/D1; Michelson 12411225 ADHD RCT lack residual-under-NET-abolish arms. Adjacent Yang 19387424 Slc6a2 haplotype↔response is pharmacogenetics not LOF residual/necessity; Swanson 16427661 regional NE is mechanism adjacent.
- Lock same-panel acute/subacute rodent (or NHP Gamo-class) WM / attention with atomoxetine ± Slc6a2 LOF or NET-matched challenge; no dosing; NOT MB/MAOI; not N15–N24 clones; orthosteric_drift=false; do not burn ip_class=none; do not treat α2-downstream as NET abolish.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Xu_Slc6a2_NET_KO_tool | LITERATURE | Mice lacking norepinephrine transporter (Slc6a2/NET KO) vs WT; NE clearance / extracellular NE / antidepressant-like / psychostimulant locomotor assays (Xu Nat Neurosci 2000) | NET KO prolongs NE clearance, elevates extracellular NE, yields antidepressant-like behaviour and psychostimulant locomotor supersensitivity (PMID 10769386 / DOI 10.1038/74839) — KO tool prior; no atomoxetine WM/attention residual-under-abolish arm |
| Bymaster_atomoxetine_NET_mechanism_PFC_NE_DA | LITERATURE | Atomoxetine selective NET inhibitor; extracellular NE and DA in PFC vs SERT/DAT selectivity (Bymaster Neuropsychopharmacology 2002) | Atomoxetine is NET-selective and increases extracellular NE and DA in PFC (PMID 12431845 / DOI 10.1016/S0893-133X(02)00346-9) — NET-mechanism attribution prior; not residual-under-abolish WM H2H |
| Gamo_atomoxetine_PFC_WM_phenotype_alpha2_D1_adjacent | LITERATURE | Monkeys; prefrontal WM ± atomoxetine challenged with idazoxan (α2) or SCH23390 (D1) (Gamo JAACAP 2010) | Atomoxetine enhances prefrontal WM; benefit challenged by idazoxan or SCH23390 (PMID 20855046 / DOI 10.1016/j.jaac.2010.06.015) — WM phenotype prior + α2/D1 downstream; α2 ≠ NET (not NET abolish residual/necessity) |
| Michelson_once_daily_atomoxetine_ADHD_RCT_phenotype | LITERATURE | Children/adolescents ADHD RCT; once-daily atomoxetine vs placebo (Michelson Am J Psychiatry 2002) | Once-daily atomoxetine improves ADHD attention phenotype vs placebo (PMID 12411225 / DOI 10.1176/appi.ajp.159.11.1896) — phenotype prior; no NET-abolish residual arm |
| matched_residual_atomoxetine_under_NET_abolish_of_NET_class_attribution_H2H | UNKNOWN | Same acute/subacute rodent (or NHP Gamo-class) WM / attention panel — atomoxetine ± Slc6a2 LOF or NET-matched abolish condition that abolishes NET-class attribution; score residual atomoxetine phenotype under abolish (± optional cell/SPR / NET occupancy overlay after lock) | dedicated residual-positive atomoxetine under Slc6a2 LOF or NET-matched block that abolishes NET-class attribution not found (soft-complete Q_resid_tight NON-MATCH residual-positive; Q_xu_atom=0; Q_atom_net_ko=DAT-KO NON-MATCH; genetic WM necessity-abolish H2H NOT FOUND; phenotype ≠ residual; α2-downstream ≠ NET abolish) — UNKNOWN + missing_search; do not invent residual; do not invent necessity kill |
| residual_atomoxetine_phenotype_ge_50pct_of_alone_when_NET_class_abolished | PREDICTION | Pre-registered acute/subacute rodent (or NHP Gamo-class) WM / attention panel; NET-class arm must show abolished attribution under Slc6a2 LOF or NET-matched blockade; atomoxetine arm scored for residual phenotype vs atomoxetine-alone under the same condition | residual atomoxetine WM / attention phenotype ≥50% of atomoxetine-alone (WM / attention units as pre-specified) while NET-class attribution is abolished under the same Slc6a2 LOF or NET-matched blockade; α/N pre-specified — do not invent observed Δ or dosing |
| competing_abolish_fail_or_atomoxetine_null_or_underpowered_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual failure/success is only failure of abolish condition to kill NET-class attribution, atomoxetine-alone null, underpowered strata, or assay-identity mismatch (phenotype ≠ residual; NET-mechanism ≠ residual-under-abolish; α2-downstream Gamo idazoxan ≠ NET abolish; DAT-KO ≠ NET LOF) | abolish-fail-to-kill / atomoxetine-alone-null / underpowered-strata / assay-mismatch allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove same-panel contrast of residual atomoxetine WM / attention phenotype under Slc6a2 LOF or NET-matched blockade that abolishes NET-class attribution: Without the abolish×residual H2H on a Gamo-class WM/attention panel with an atomoxetine arm, separate NET-mechanism LITERATURE and phenotype/tool LITERATURE cannot show net-insufficiency as a residual-positive kill.
- remove verified abolish gate (Slc6a2 LOF or NET-matched blockade that abolishes NET-class attribution) plus atomoxetine-alone comparator as the residual gate: Without verified NET-class abolish and atomoxetine-alone comparator under the same condition, residual atomoxetine is just “another catecholamine agent under nonspecific challenge,” not an assumption-kill of NET-class sufficiency for the atomoxetine phenotype.
- remove N15≠N25 + N16≠N25 + N17≠N25 + N18≠N25 + N19≠N25 + N20≠N25 + N21≠N25 + N22≠N25 + N23≠N25 + N24≠N25 + N1–N24≠proof + soft-complete-empty≠novelty + phenotype≠residual + NET-mechanism≠residual + α2-downstream≠NET-abolish + genetic-necessity-H2H-not-invented + NOT-MB/MAOI + ip_class≠none + orthosteric_drift=false discipline: Treating N15–N24 residuals (especially N15 DAT / N22 AMPT / N23 α2 as if they were NET abolish), Bymaster mechanism as residual-under-abolish, Xu/Gamo/Michelson phenotype as residual H2H, Gamo idazoxan as NET abolish, empty genetic necessity as invented necessity kill, or empty/adjacent PubMed as already deciding residual atomoxetine under NET abolish would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered acute/subacute rodent (or NHP Gamo-class) WM / attention panel, under Slc6a2 genetic LOF or a NET-matched blockade that abolishes NET-class attribution, residual atomoxetine WM / attention phenotype falls below 50% of atomoxetine-alone (WM / attention units as pre-specified) — so NET-class sufficiency for the atomoxetine phenotype survives and net-insufficiency fails — when abolish-gate, atomoxetine-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock acute/subacute rodent (or NHP Gamo-class) WM / attention assay identity, NET-class attribution abolish gate under Slc6a2 LOF or named NET-matched blockade, atomoxetine-alone comparator, and optional cell/SPR / NET occupancy overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N20 or N21 or N22 or N23 or N24 or N1–N24 as proof — especially N15 ≠ N25 (DAT ≠ NET); N22 ≠ N25 (AMPT ≠ NET LOF); N23 ≠ N25 (α2 ≠ NET; do not treat Gamo idazoxan×ATM as NET abolish); no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; not N20 Bacopa/AChE clone; not N21 nicotine/nAChR clone; not N22 tyrosine/AMPT clone; not N23 guanfacine/alpha2 clone; not N24 caffeine/A2A clone; orthosteric_drift=false; do not burn ip_class=none; do not invent residual; do not invent genetic necessity kill.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=net-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ atomoxetine×NET; DAT ≠ NET); N16 (plasma-Cr/PCr ≠ atomoxetine×NET); N17 (Hericium×NGF/TrkA ≠ atomoxetine×NET); N18 (theanine-adenosine ≠ atomoxetine×NET); N19 (Rhodiola-HPA ≠ atomoxetine×NET); N20 (Bacopa×AChE ≠ atomoxetine×NET); N21 (nicotine×nAChR ≠ atomoxetine×NET); N22 (tyrosine/AMPT ≠ atomoxetine×NET; AMPT ≠ NET LOF); N23 (guanfacine×alpha2 ≠ atomoxetine×NET; α2 ≠ NET; ESPECIALLY DISTINCT); N24 (caffeine×A2A ≠ atomoxetine×NET); N2 holds sole ip_class=none; N1–N24 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N25.card.md card_sha256: 8840c5727d1e9bc70aa777f88224d6f73b87b17cb05855a54156f230171afa91
Mol Labs public report: PENDING dual-publish